Cargando…

Compatibility of intravitreally applied epidermal growth factor and amphiregulin

INTRODUCTION: To examine the compatibility of intravitreally injected epidermal growth factor (EGF) and amphiregulin as EGF family member. METHODS: Four rabbits (age: 4 months; body weight: 2.5 kg) received three intravitreal injections of EGF (100 ng) uniocularly in monthly intervals and underwent...

Descripción completa

Detalles Bibliográficos
Autores principales: Bikbov, Mukharram M., Khalimov, Timur A., Cerrada-Gimenez, Marc, Ragauskas, Symantas, Kalesnykas, Giedrius, Jonas, Jost B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172503/
https://www.ncbi.nlm.nih.gov/pubmed/33713254
http://dx.doi.org/10.1007/s10792-021-01761-w
_version_ 1783702542891352064
author Bikbov, Mukharram M.
Khalimov, Timur A.
Cerrada-Gimenez, Marc
Ragauskas, Symantas
Kalesnykas, Giedrius
Jonas, Jost B.
author_facet Bikbov, Mukharram M.
Khalimov, Timur A.
Cerrada-Gimenez, Marc
Ragauskas, Symantas
Kalesnykas, Giedrius
Jonas, Jost B.
author_sort Bikbov, Mukharram M.
collection PubMed
description INTRODUCTION: To examine the compatibility of intravitreally injected epidermal growth factor (EGF) and amphiregulin as EGF family member. METHODS: Four rabbits (age: 4 months; body weight: 2.5 kg) received three intravitreal injections of EGF (100 ng) uniocularly in monthly intervals and underwent ocular photography, tonometry, biometry, and optical coherence tomography. After sacrificing the rabbits, the globes were histomorphometrically examined. In a second study part, eyes of 22 guinea pigs (age: 2–3 weeks) received two intravitreal administrations of amphiregulin (10 ng) or phosphate buffered solution (PBS) in 10-day interval, or were left untouched. Ten days after the second injection, the guinea pigs were sacrificed, the enucleated eyes underwent histological and immune-histological examinations. RESULTS: The rabbit eyes with EGF injections versus the contralateral untouched eyes did not show significant differences in intraocular pressure (7.5 ± 2.4 mmHg vs. 6.8 ± 2.2 mmHg; P = 0.66), retinal thickness (158 ± 5 µm vs. 158 ± 3 µm; P = 1.0), cell counts in the retinal ganglion cell layer (3.3 ± 1.7 cells/150 µm vs. 3.0 ± 1.4 cells/150 µm; P = 0.83), inner nuclear layer (46.4 ± 23.2 cells/150 µm vs. 39.6 ± 6.4 cells/150 µm; P = 0.61), and outer nuclear layer (215 ± 108 cells/150 µm vs. 202 ± 47 cells/150 µm; P = 0.83), or any apoptotic retinal cells. The guinea pig eyes injected with amphiregulin versus eyes with PBS injections did not differ (P = 0.72) in the degree of microglial activation, and both groups did not differ from untouched eyes in number of apoptotic retinal cells and retinal gliosis. CONCLUSIONS: Intravitreal applications of EGF (100 ng) in rabbits nor intravitreal applications of amphiregulin (10 ng) in guinea pigs led to intraocular specific inflammation or any observed intraocular destructive effect. The findings support the notion of a compatibility of intraocular applied EGF and amphiregulin.
format Online
Article
Text
id pubmed-8172503
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-81725032021-06-07 Compatibility of intravitreally applied epidermal growth factor and amphiregulin Bikbov, Mukharram M. Khalimov, Timur A. Cerrada-Gimenez, Marc Ragauskas, Symantas Kalesnykas, Giedrius Jonas, Jost B. Int Ophthalmol Original Paper INTRODUCTION: To examine the compatibility of intravitreally injected epidermal growth factor (EGF) and amphiregulin as EGF family member. METHODS: Four rabbits (age: 4 months; body weight: 2.5 kg) received three intravitreal injections of EGF (100 ng) uniocularly in monthly intervals and underwent ocular photography, tonometry, biometry, and optical coherence tomography. After sacrificing the rabbits, the globes were histomorphometrically examined. In a second study part, eyes of 22 guinea pigs (age: 2–3 weeks) received two intravitreal administrations of amphiregulin (10 ng) or phosphate buffered solution (PBS) in 10-day interval, or were left untouched. Ten days after the second injection, the guinea pigs were sacrificed, the enucleated eyes underwent histological and immune-histological examinations. RESULTS: The rabbit eyes with EGF injections versus the contralateral untouched eyes did not show significant differences in intraocular pressure (7.5 ± 2.4 mmHg vs. 6.8 ± 2.2 mmHg; P = 0.66), retinal thickness (158 ± 5 µm vs. 158 ± 3 µm; P = 1.0), cell counts in the retinal ganglion cell layer (3.3 ± 1.7 cells/150 µm vs. 3.0 ± 1.4 cells/150 µm; P = 0.83), inner nuclear layer (46.4 ± 23.2 cells/150 µm vs. 39.6 ± 6.4 cells/150 µm; P = 0.61), and outer nuclear layer (215 ± 108 cells/150 µm vs. 202 ± 47 cells/150 µm; P = 0.83), or any apoptotic retinal cells. The guinea pig eyes injected with amphiregulin versus eyes with PBS injections did not differ (P = 0.72) in the degree of microglial activation, and both groups did not differ from untouched eyes in number of apoptotic retinal cells and retinal gliosis. CONCLUSIONS: Intravitreal applications of EGF (100 ng) in rabbits nor intravitreal applications of amphiregulin (10 ng) in guinea pigs led to intraocular specific inflammation or any observed intraocular destructive effect. The findings support the notion of a compatibility of intraocular applied EGF and amphiregulin. Springer Netherlands 2021-03-13 2021 /pmc/articles/PMC8172503/ /pubmed/33713254 http://dx.doi.org/10.1007/s10792-021-01761-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Bikbov, Mukharram M.
Khalimov, Timur A.
Cerrada-Gimenez, Marc
Ragauskas, Symantas
Kalesnykas, Giedrius
Jonas, Jost B.
Compatibility of intravitreally applied epidermal growth factor and amphiregulin
title Compatibility of intravitreally applied epidermal growth factor and amphiregulin
title_full Compatibility of intravitreally applied epidermal growth factor and amphiregulin
title_fullStr Compatibility of intravitreally applied epidermal growth factor and amphiregulin
title_full_unstemmed Compatibility of intravitreally applied epidermal growth factor and amphiregulin
title_short Compatibility of intravitreally applied epidermal growth factor and amphiregulin
title_sort compatibility of intravitreally applied epidermal growth factor and amphiregulin
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172503/
https://www.ncbi.nlm.nih.gov/pubmed/33713254
http://dx.doi.org/10.1007/s10792-021-01761-w
work_keys_str_mv AT bikbovmukharramm compatibilityofintravitreallyappliedepidermalgrowthfactorandamphiregulin
AT khalimovtimura compatibilityofintravitreallyappliedepidermalgrowthfactorandamphiregulin
AT cerradagimenezmarc compatibilityofintravitreallyappliedepidermalgrowthfactorandamphiregulin
AT ragauskassymantas compatibilityofintravitreallyappliedepidermalgrowthfactorandamphiregulin
AT kalesnykasgiedrius compatibilityofintravitreallyappliedepidermalgrowthfactorandamphiregulin
AT jonasjostb compatibilityofintravitreallyappliedepidermalgrowthfactorandamphiregulin